Free tool
FAERS Monitor: Lamictal Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022509 or its brand name (Lamictal Xr, Lamotrigine). Reports on generic versions are filed under their own applications.
Reports
132,921
Serious
95,830
72% of reports
Hospitalization
40,863
Death reported
11,516
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective10,467
- rash8,737
- seizure6,882
- nausea6,498
- off label use6,324
- fatigue6,299
- dizziness6,140
- headache5,868
- depression5,290
- vomiting4,887
- somnolence4,571
- drug interaction4,529
- pyrexia4,529
- anxiety4,518
- toxicity to various agents4,374
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,016 |
| 2005 | 3,052 |
| 2006 | 3,557 |
| 2007 | 3,880 |
| 2008 | 2,377 |
| 2009 | 4,901 |
| 2010 | 3,808 |
| 2011 | 4,992 |
| 2012 | 5,304 |
| 2013 | 4,731 |
| 2014 | 5,234 |
| 2015 | 7,311 |
| 2016 | 7,568 |
| 2017 | 7,268 |
| 2018 | 8,262 |
| 2019 | 8,660 |
| 2020 | 7,763 |
| 2021 | 7,290 |
| 2022 | 6,688 |
| 2023 | 7,031 |
| 2024 | 7,715 |
| 2025 | 7,912 |
| 2026 | 5,600 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,921,238 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| seizureSignal | 6,882 | 10.0 | 9.7 | 52,458 |
| drug interactionSignal | 4,529 | 4.6 | 4.5 | 12,574 |
| toxicity to various agentsSignal | 4,374 | 4.2 | 4.1 | 10,415 |
| depressionSignal | 5,290 | 3.7 | 3.6 | 10,496 |
| somnolenceSignal | 4,571 | 3.7 | 3.5 | 8,685 |
| rashSignal | 8,737 | 3.2 | 3.2 | 13,348 |
| anxietySignal | 4,518 | 2.5 | 2.5 | 4,193 |
| pyrexiaSignal | 4,529 | 2.1 | 2.0 | 2,566 |
| dizziness | 6,140 | 2.0 | 1.9 | 2,919 |
| vomiting | 4,887 | 1.7 | 1.6 | 1,271 |
| headache | 5,868 | 1.5 | 1.4 | 950 |
| nausea | 6,498 | 1.3 | 1.3 | 468 |
| fatigue | 6,299 | 1.3 | 1.3 | 403 |
| drug ineffective | 10,467 | 1.3 | 1.2 | 589 |
| off label use | 6,324 | 1.1 | 1.1 | 118 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.